stockrowHUTCHMED (China) Limited Sponsored ADR
HCM Healthcare Drug Manufacturers Specialty & Generic
HUTCHMED (China) Limited Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $548.5 million, down 13.0% from fiscal 2024.
Follow HCM
Alert me
HUTCHMED (China) Limited Sponsored ADR (HCM) P/B ratio
HUTCHMED (China) Limited Sponsored ADR has no meaningful P/B ratio: its trailing twelve-month book value is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Jun 2023 | 12.7× | (42.89%) |
| Dec 2022 | 22.2× | 76.60% |
| Jun 2022 | 12.6× | 103.37% |
| Jun 2021 | 6.2× | 534.37% |
| 10 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| BCRX BioCryst Pharmaceuticals, Inc. compare | n/m |
| ALVO Alvotech compare | n/m |
| RGC Regencell Bioscience Holdings Limited compare | n/m |
| HCM HUTCHMED (China) Limited Sponsored ADR | n/m |
| PRGO Perrigo Company plc compare | 0.9× |
| PBH Prestige Consumer Healthcare Inc. compare | 1.1× |
| ANIP ANI Pharmaceuticals, Inc. compare | 2.3× |
| TRLV Trulieve Cannabis Corp. compare | 2.8× |
| XERS Xeris Biopharma Holdings, Inc. compare | 48.0× |
| Drug Manufacturers Specialty & Generic industry median | 1.8× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on HCM
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement